HIV - Human Immunodeficiency VirusPrimoAVIHNCT07691424
Impact of Migration History and Social Conditions on the Immuno-virological Control of HIV in Migrants in France
An observational study of HIV - Human Immunodeficiency Virus and Socio-economic Status, run by University Hospital, Clermont-Ferrand at 1 site in France.
Trial summary
Migrants living with HIV - whether the infection was diagnosed in their country of origin or in France- frequently experience vulnerabilities related to their migration trajectories and often face socioeconomic and administrative instability upon arrival . Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- HIV - Human Immunodeficiency Virus, Socio-economic Status, Migrants
- How many people
- 150 participants
- Where
- 1 siteFrance
- Study dates
- 15 Jul 2026to 15 Feb 2030
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults patients living with HIV and receiving care at Clermont-Ferrand Univeristy Hospital between 2010 and 2022
Who may be able to join
- Adults (≥18 years of age);
- Migrant patients (i.e., individuals who entered France for the first time from another country) receiving care at Clermont-Ferrand University Hospital between January 1, 2010, and December 31, 2022, whose HIV infection was either known at the time of their arrival in France or diagnosed within 12 months after their arrival in France.
- Non-inclusion Criteria:
- Patients who declined to participate in the study;
- Patients who do not speak French and for whom no interpretere was available
- Adults subject to a legal protection measure (i.e., under guardianship, curatorship, or judicial protection)
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
Clermont-Ferrand University Hospital
Clermont-Ferrand, France, 63000
Aida ZAGHDOUDI, Medical Doctor
About this study
Migrants living with HIV - whether the infection was diagnosed in their country of origin or in France- frequently experience vulnerabilities related to their migration trajectories and often face socioeconomic and administrative instability upon arrival .
The primary outcome of this study is to compare the immunovirological efficacy of antiretroviral therapy among migrants living with HIV patients according to their social and administrative status.
- Keywords
- HIV, socio-economic status, vulnerability, immuno-virological status, migrants
- Medical subject headings
- Acquired Immunodeficiency Syndrome
What is being measured
The primary outcome is the main question the study is designed to answer.
HIV immuno-virological status
To compare the immuno-virological efficacy of antiretroviral therapy according to the social and administrative status of HIV-infected migrants
Measured: Submission to the Research Ethics Committee (REC): February 2026 REC approval: May 2026 Study initiation : July 2026 Recruitment period: 18 months Total study duration: 30 months Estimated study completed : january 2029
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jul 2026
- Study start15 Jul 2026 (estimated)
- Primary completion15 Feb 2029 (estimated)
- Study completion15 Feb 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HIV - Human Immunodeficiency VirusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Clermont-Ferrand
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Aida ZAGHDOUDI, Principal investigator, University Hospital, Clermont-Ferrand
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07691424
- Sponsor's protocol ID
- RNI 2025 ZAGHDOUDI
- Other IDs
- ANSM
- Acronym
- PrimoAVIH
- Status last verified
- Jun 2026
- First submitted
- 2 Jul 2026
- Last updated
- 8 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No